Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-09-14
2002-08-20
Higel, Floyd D. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S377000, C514S399000, C514S400000, C514S403000, C514S406000, C514S602000, C546S274100, C546S290000, C548S225000, C548S228000, C548S229000, C548S235000, C548S314700, C548S315100, C548S315400, C548S335500, C548S338500, C548S359500, C548S375100, C548S376100, C548S377100, C548S549000, C548S556000, C564S084000, C564S091000
Reexamination Certificate
active
06436967
ABSTRACT:
FIELD OF THE INVENTION
This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to prodrugs of compounds which selectively inhibit cyclooxygenase-2.
BACKGROUND OF THE INVENTION
The use of non-steroidal antiinflammatory drugs (NSAIDs) in treating pain and the swelling associated with inflammation also produce severe side effects, including life threatening ulcers. The recent discovery of an inducible enzyme associated with inflammation (“prostaglandin G/H synthase II” or “cyclooxygenase-2 (COX-2)”) provides a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects.
Compounds which selectively inhibit cyclooxygenase-2 have been described. U.S. Pat. No. 5,380,738 describes oxazoles which selectively inhibit cyclooxygenase-2. U.S. Pat. No. 5,344,991 describes cyclopentenes which selectively inhibit cyclooxygenase-2. U.S. Pat. No. 5,393,790 describes spiro compounds which selectively inhibit cyclooxygenase-2. WO94/15932 describes thiophene and furan derivatives which selectively inhibit cyclooxygenase-2. WO94/27980 describes oxazoles which selectively inhibit cyclooxygenase-2. WO94/13635 describes compounds which selectively inhibit cyclooxygenase-2. WO94/20480 describes compounds which selectively inhibit cyclooxygenase-2. WO95/15316 describes pyrazolyl sulfonamide derivatives which selectively inhibit cyclooxygenase-2. However, in some circumstances, prodrugs of antiinflammatory compounds are advantageous, especially where the prodrugs have increased water solubility or delayed onset of action.
Substituted sulfonamides have been described. Pyrazolyl-sulfonylureas have been described as having possible hypoglycemic activity [H. Faid-Allah and H. Mokhtar,
Ind. J. Chem
, 27, 245 (1988)]. JP 1,045,374 describes water soluble tetrazolium compounds useful in assays for determining reducing substances. D. Mukerjee et al [
Acta. Pharma. Jugosl
., 31, 151 (1981)] describe tetrazolium sulfonamides as antiviral agents. JP 4,277,724 describes triphenyl pyrazolines as nonlinear optical material. JP 5,323,522 describes the use of heterocyclic compounds in black and white photographic material. U.S. Pat. No. 5,389,635 describes substituted imidazoles as angiotensin II antagonists. U.S. Pat. No. 5,387,592 describes substituted benzimidazole derivatives as angiotensin II antagonists. G. Dorofeenko et al [
Khim. Farm. Zh
., 16, 920 (1982)] describe pyridinium salts as antiviral agents. U.S. Pat. No. 5,338,749 describes diaryl-substituted heterocyclyl compounds as antiarthritis agents. WO94/26731 describes thiophene compounds which selectively inhibit cyclooxygenase-2. WO95/00501 describes compounds which selectively inhibit cyclooxygenase-2, and specifically, 3-(4-(trifluoroacetylaminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene is described. T. Ivanov [
Mh. Chem
., 97, 1499 (1966)] describes the preparation of diarylindone derivatives as possible indicators, and 2-(4-(N-methylaminosulfonyl)phenyl)-3-phenylindone is specifically described.
J. Larsen and H. Bundgaard [
Int. J. Pharmaceutics
, 37, 87 (1987)] describe the evaluation of N-acylsulfonamides as potential prodrug derivatives. J. Larsen et al [
Int. J. Pharmaceutics
, 47, 103 (1988)] describe the evaluation of N-methylsulfonamides as potential prodrug derivatives.
There currently exists a need for compounds suitable for injectable antiinflammatory compositions. The compounds of the present invention are found to show usefulness as prodrugs.
REFERENCES:
patent: 5338749 (1994-08-01), Wuest et al.
patent: 5344991 (1994-09-01), Reitz et al.
patent: 5380738 (1995-01-01), Norman et al.
patent: 5387592 (1995-02-01), Bradbury et al.
patent: 5389635 (1995-02-01), Olson
patent: 5393790 (1995-02-01), Reitz et al.
patent: 5616601 (1997-04-01), Khanna et al.
patent: 5633272 (1997-05-01), Talley et al.
patent: 1045374 (1989-02-01), None
patent: 4277724 (1992-10-01), None
patent: 5323522 (1993-12-01), None
patent: WO94/13635 (1994-06-01), None
patent: WO94/15932 (1994-07-01), None
patent: WO94/20480 (1994-09-01), None
patent: WO94/26731 (1994-11-01), None
patent: WO94/27980 (1994-12-01), None
patent: WO95/00501 (1995-01-01), None
patent: WO95/15316 (1995-06-01), None
H. Faid-Allah and H. Mokhtar,Ind. J. Chem, 27, 245-249 (1988).
D Murkerjee et al,Acta. Pharma. Jugosl., 31, 151-158 (1981).
G. Dorofeenko et al,Khim. Farm. Zh., 16, 920-923, (1982).
T. Ivanov,Mh. Chem., 97, 1499-1509 (1966).
J. Larsen and H. Bundagaard, Int. J. Pharmaceutics, 37, 87-95 (1987).
J. Larsen et al, Int. J. Pharmaceutics, 47, 103-110 (1988).
Y. LeBlanc et al, Bio & Med. Chem. Letters 5(18), 2123-2128 (1995).
Bertenshaw Stephen
Brown David L
Carter Jeffery
Graneto Matthew J
Khanna Ish K
Higel Floyd D.
Pharmacia Corporation
Sackey Ebenezer
Senniger Powers Leavitt & Roedel
LandOfFree
Process for preparing prodrugs of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for preparing prodrugs of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparing prodrugs of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2906910